After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version

Right on the heels of an FDA approval for the closely watched Alzheimer's disease drug Leqembi in an intravenous dose, Eisai is touting "promising" findings that the company says support the case for a subcutaneous version.